Epidermolytic hyperkeratosis (EH) is a hereditary disease that belongs to the group of keratodermas and is characterized by abnormal thickening of the stratum corneum of the epidermis, which leads to the formation of characteristic painful cracks, crusts and papules on the skin. This disease manifests itself at an early age and can have varying degrees of severity, affecting both the patient's quality of life and his psychoemotional state. EH is associated with mutations in genes responsible for the structure and function of keratinocytes, which disrupts the keratinization process and leads to clinical manifestations associated with itching and inflammation.
History of the disease and interesting historical facts
Epidermolytic hyperkeratosis was first described in the literature at the beginning of the 20th century. It attracted the attention of dermatologists due to its expressiveness and rarity. For decades, researchers have tried to understand the mechanism of the disease, which led to the identification of the genes and pathogenetic processes involved. Interestingly, some studies show that descriptions of similar conditions can be found even in the works of ancient Greek doctors, but the modern classification was based only on the study of genetic and clinical aspects. In recent years, interest in EG has increased significantly, which is associated with the development of molecular genetics and the advent of DNA sequencing technologies, which allowed a more in-depth study of mutational mechanisms.
Epidemiology
According to epidemiological studies, the prevalence of epidermolytic hyperkeratosis ranges from 1 to 3 cases per 100,000 people. It is known that the disease is more often observed in people with a historically confirmed family history. Specialized clinics note a higher incidence in certain populations with a high degree of inbreeding. According to available data, men and women suffer from EG with approximately the same frequency, but differences in severity and manifestations can be observed depending on genetic factors.
Genetic predisposition to this disease
Epidermolytic hyperkeratosis is a hereditary disease transmitted in an autosomal dominant or autosomal recessive manner. Studies have confirmed the presence of mutations in the KRT1, KRT10 and KRT17 genes, where any changes can lead to a disruption of the keratin structure, which in turn disrupts the keratinization process. An example is a mutation in the KRT1 gene, which leads to the formation of abnormal keratins, which causes the characteristic symptoms of the disease. Genetic tests for mutations can be useful for diagnosis and genetic counseling, especially in parents with a family history of the disease.
Risk factors for the development of this disease
Although EG is a hereditary disease, some factors can aggravate its course and manifestation. Physical risk factors for EG include:
- Frequent exposure to irritating substances on the skin (detergents, chemicals).
- Friction and mechanical damage to the skin (insufficient protection during physical activity).
- Changes in temperature conditions (cooling or overheating).
Chemical risk factors include:
- Contact with allergens, which can trigger allergic reactions and worsen symptoms.
Thus, well-structured preventive behavior can help reduce the risk of exacerbations and improve the patient's quality of life.
Diagnosis of this disease
Diagnosis of epidermolytic hyperkeratosis is based on a combination of clinical signs, family history and molecular genetic analysis. The main symptoms of the disease include:
- Thickening of the stratum corneum of the skin.
- The appearance of cracks and crusts.
- Itching and discomfort.
- Inflammatory changes in the skin.
Laboratory tests may include:
- Dermoscopy to visualize the epidermis at the cellular level.
- Cytological examination of skin scrapings.
Radiological examinations are generally not used in the diagnosis of EG, but may be required to exclude other skin diseases. Differential diagnosis should be made with other forms of keratoderma and dermatitis. It is important to consider the possibility of concomitant diseases, which may complicate the clinical picture.
Treatment
An acute episode of epidermolytic hyperkeratosis requires a comprehensive approach to treatment. General treatment includes:
- Elimination of provoking factors (avoidance of triggers).
- Treatment of damaged areas of the skin with local emollients for moisturizing.
Pharmacological treatment may include:
- Use of corticosteroids to reduce inflammation.
- Calcineurin inhibitors in severe cases to control inflammation.
Surgical procedures may be necessary in cases of crusted lesions where infection is possible, and other therapies such as physical therapy and physiotherapy procedures to stimulate skin regeneration may also be recommended.
List of medications used to treat this disease
Among the drugs used for the treatment of EG, the following can be distinguished:
- Creams containing corticosteroids (eg, betamethasone).
- Creams with calcineurin inhibitors (tacrolimus).
- Emollients for moisturizing and maintaining the skin's barrier function.
These agents help control the severity of symptoms and minimize their impact on patients' quality of life.
Disease monitoring
Monitoring of patients with epidermolytic hyperkeratosis includes regular follow-up examinations to assess the dynamics of symptoms and possible complications. The prognosis is generally good, but some patients may develop infections or unprotected areas of skin that require additional intervention. Complications may include the formation of keloid scars at the site of injury or secondary infections.
Age-related features of the disease
Epidermolytic hyperkeratosis can manifest itself in various age groups, but the most severe forms are observed in children. Signs of the disease can appear from the first days of life, which requires monitoring of the skin condition and early intervention. In adolescence, patients often face psychological difficulties due to the impact of appearance on self-esteem. In older people, the disease can be exacerbated by other concomitant dermatoses or deterioration of general health.
Questions and Answers
- What is the nature of epidermolytic hyperkeratosis? It is a genetic disorder associated with mutations in keratin genes, resulting in the formation of an abnormal stratum corneum of the skin.
- How is EG diagnosed? Diagnosis is based on clinical observations, family history and molecular genetic testing.
- What are the main treatments for EG? Treatment includes topical corticosteroids, emollients, and, in some cases, surgery.
- Can the disease affect the quality of life? Yes, epidermolytic hyperkeratosis can cause physical discomfort and emotional difficulties.
- What is the likelihood of inheriting the disease? The disease is transmitted in an autosomal dominant or autosomal recessive manner, depending on the type of mutation.
Dr. Oleg Korzhikov, a dermatologist, recommends a comprehensive approach to treating epidermolytic hyperkeratosis, paying attention to both medical and non-medical care. It is important to maintain constant contact with a dermatologist, monitor the condition of the skin and avoid factors that contribute to an exacerbation of the disease. He also advises considering the possibility of physical and psychological training to improve the general condition and quality of life of patients.
